Commonwealth Equity Services’s Crescent Biopharma CBIO Stock Holding History

Commonwealth Equity Services’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$15K	–	3951
2023 Q3	$15K	Hold	100	–	–	﹤0.01%	3753
2023 Q2	$17K	Hold	100	–	–	﹤0.01%	3757
2023 Q1	$12K	Hold	100	–	–	﹤0.01%	3710
2022 Q4	$30K	Hold	100	–	–	﹤0.01%	3569
2022 Q3	$5K	Hold	100	–	–	﹤0.01%	3641
2022 Q2	$5K	Hold	100	–	–	﹤0.01%	3647
2022 Q1	$11K	Hold	100	–	–	﹤0.01%	3684
2021 Q4	$14K	Hold	100	–	–	﹤0.01%	3618
2021 Q3	$21K	Hold	100	–	–	﹤0.01%	3545
2021 Q2	$23K	Hold	100	–	–	﹤0.01%	3495
2021 Q1	$30K	Buy	+100	New	+$35.8K	﹤0.01%	3362

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services's CBIO Position: Q4 2023 in Review

Commonwealth Equity Services sold out of Crescent Biopharma (CBIO) in Q4 2023, closing a stake of 100 shares — an estimated $15K sold.

Commonwealth Equity Services first reported a position in CBIO in Q1 2021 and held it in 11 quarters. The position peaked at $30K in Q4 2022. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2023.

Commonwealth Equity Services reported no remaining Crescent Biopharma position as of Q4 2023 after selling out during the quarter.
Commonwealth Equity Services sold 100 Crescent Biopharma shares in Q4 2023, an estimated $15K.
Commonwealth Equity Services first reported a position in Crescent Biopharma in Q1 2021 and held it in 11 quarters.
Commonwealth Equity Services's Crescent Biopharma position peaked at $30K in Q4 2022.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2023.

Based on Commonwealth Equity Services's 13F filing for Q4 2023, filed 6 Feb 2024.